Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: GlaxoSmithKline plc

Market Cap 7.92TCr 11TCr 9.18TCr 8.46TCr 15TCr 10,10500Cr 15TCr 1LCr 39TCr 4,91800Cr 40TCr 39TCr 17,03000Cr P/E Ratio 2026 *
12.7x
P/E Ratio 2027 * 11.8x
Enterprise Value 9.35TCr 13TCr 11TCr 9.98TCr 18TCr 11,92300Cr 18TCr 1,17900Cr 46TCr 5,80300Cr 47TCr 46TCr 20,09400Cr EV / Sales 2026 *
2.77x
EV / Sales 2027 * 2.55x
Free-Float
92.3%
Yield 2026 *
3.53%
Yield 2027 * 3.69%
Manager TitleAgeSince
Chief Executive Officer - 01/01/2026
Director of Finance/CFO 64 01/05/2023
Chief Tech/Sci/R&D Officer - 01/12/2021
Director TitleAgeSince
Director/Board Member - 06/05/2026
Director/Board Member 64 01/01/2018
Chairman 68 01/09/2019
Change 5-day change 1-year change 3-year change Capi.($)
-2.41%+0.14%+39.53%+154.43% 1,01000Cr
+1.07%+3.48%+53.75%+50.64% 58TCr
+1.32%+0.22%+18.35%+65.35% 40TCr
+0.77%0.00%+19.99%+16.80% 33TCr
-1.42%-1.44%+45.50%+8.37% 29TCr
-0.85%-2.86%+22.05%+13.80% 28TCr
+0.44%+3.48%+24.48%+34.39% 28TCr
+1.66%+1.20%-44.67%-47.49% 20TCr
+0.32%+1.61%+19.48%+63.42% 19TCr
Average -0.28%+0.99%+22.05%+39.97% 39.63TCr
Weighted average by Cap. -0.80%+1.00%+29.84%+66.16%

Financials

2026 *2027 *
Net sales 3.38TCr 4.53TCr 3.92TCr 3.61TCr 6.33TCr 4,31000Cr 6.43TCr 43TCr 17TCr 2,09800Cr 17TCr 17TCr 7,26400Cr 3.55TCr 4.76TCr 4.11TCr 3.79TCr 6.65TCr 4,52600Cr 6.75TCr 45TCr 17TCr 2,20300Cr 18TCr 17TCr 7,62800Cr
Net income 626.62Cr 841.1Cr 726.46Cr 669.44Cr 1.17TCr 80TCr 1.19TCr 7.9TCr 3.08TCr 39TCr 3.16TCr 3.09TCr 1,34700Cr 666.92Cr 895.2Cr 773.18Cr 712.49Cr 1.25TCr 85TCr 1.27TCr 8.41TCr 3.28TCr 41TCr 3.36TCr 3.29TCr 1,43400Cr
Net Debt 1.43TCr 1.91TCr 1.65TCr 1.52TCr 2.67TCr 1,81800Cr 2.71TCr 18TCr 7.01TCr 89TCr 7.18TCr 7.03TCr 3,06400Cr 1.12TCr 1.5TCr 1.3TCr 1.2TCr 2.1TCr 1,42800Cr 2.13TCr 14TCr 5.5TCr 69TCr 5.64TCr 5.52TCr 2,40600Cr
Logo GlaxoSmithKline plc
GSK plc is the world's No. 2 pharmaceutical group. Net sales break down by family of products as follows: - pharmaceutical products (41.3%): intended mainly for HIV infection (57% of net sales), immune system disorders and respiratory diseases (28.3%), and cancer (14.7%); - OTC and parapharmaceutical medicine (30.7%); - vaccines (28%). Net sales are distributed geographically as follows: the United Kingdom (2.1%), Europe (21%), the United States (51.6%), and other (25.3%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!